title: [Health impact and treatment costs of community-acquired pneumonia in children in the first level of public attention in Argentina].
abstract: Community acquired pneumonia in children remains an important cause of childhood deaths throughout the world that can be prevented by the use of antibiotics and access to medical care. Both were reduced in 2001 when Argentina suffered a severe social crisis. Among the responses to the crisis, the Remediar Program provided free essential medicines to the socially vulnerable population.
  
  
  OBJECTIVE
  Assess the health impact and costs of the provision of free medicines at the first level of public attention for childhood pneumonia.
  
  
  METHODS
  Three designs: 1. Ecological study with cross comparisons of diagnoses, prescriptions, beneficiaries by individual provinces of Remediar forms.
  
  
  METHODS
  children under 15 years old attended at 6 thousand health centres in Argentina, encompassing 24 Argentine provinces from March 2005 until February 2006. 2. Counterfactual approach. 3. Calculation of drug costs per unit of outcome.
  
  
  RESULTS
  Over 15 million prescriptions were identified, 2,420 children under 1 year, 19,205 of 1 to 4 years and 15,977 from 5 to 14 years old with pneumonia. 90% of beneficiaries received antibiotics, most often amoxicillin. In children's under 5 years of age, Remediar coverage was 27.8%, with greater impact in the poorest provinces. The likely impact was 4,322 lives saved or 310,325 years of life lost avoided if mortality without antibiotics was 20%. Indigents who had children with pneumonia saved by medicines 14.3% of their income. Each life saved could have cost US $ 6.46 and each year of life lost averted US $ 0.09.
  
  
  CONCLUSIONS
  This work highlights the impact of a low-cost health program for the treatment of vulnerable populations with childhood pneumonia in Argentina.
authors.affiliation: Programa Remediar, Hospital Nacional de Pediatría Prof. Dr. Juan P. Garrahan, Buenos Aires. rbernztein@proaps.gov.ar
authors.forename: Ricardo
authors.initials: R
authors.lastname: Bernztein
authors.forename: Ignacio
authors.initials: I
authors.lastname: Drake
mesh_terms: D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000191:economics* / Q000627:therapeutic use*; D001118:Argentina; D002648:Child; D002675:Child, Preschool; D017714:Community-Acquired Infections / Q000188:drug therapy / Q000191:economics; D003365:Costs and Cost Analysis; D006801:Humans; D007223:Infant; D017063:Outcome Assessment, Health Care; D011014:Pneumonia / Q000188:drug therapy* / Q000191:economics*; D011320:Primary Health Care; D017150:Public Sector
chemical_list: D000900:Anti-Bacterial Agents